Toggle navigation image image
Toggle navigation logologo
image image
  • About Inflarx
    • Leadership Team
    • Board
  • R&D
    • Pipeline
    • Products & Technology
      • Technology
      • Vilobelimab
      • INF904
      • IFX002
    • Clinical Development
      • Pyoderma Gangraenosum
      • COVID-19
      • cSCC
      • Clinical Trials
    • Publications & Posters
  • Investors
    • Press Releases
    • Events & Presentations
    • Financial Information
    • Share Information
    • Analyst Coverage
    • Corporate Governance
    • Annual/Extraordinary General Meetings
    • E-mail alerts
  • Career
    • Open Positions

Timothy E. Hermes

  • Home
  • About Inflarx
  • Leadership Team
  • Timothy E. Hermes
image

Timothy E. Hermes

Vice President, Commercial

Tim joined InflaRx in May 2023 as Vice President of Commercial bringing with him 35 years of biotech/pharma experience with a career ranging from sales and marketing to government affairs to commercial and government payer expertise. His work in Washington DC while Head of Government Affairs at Sunovion led to significant industry-wide changes to CMS coverage policies and to the passing of legislative language that increased patient access to Tim’s products. He has built a deep knowledge of the intricacies of the U.S. payer system due to his time in DC coinciding with the passage of the Medicare Modernization Act and later the Affordable Care Act, both of which significantly altered the payer landscape in the U.S. and whose policies are still in effect to this day. His employment history includes Pfizer, Sunovion, Endo, and Sanofi.

He has recent experience launching products into the hospital inpatient setting of care and has expert knowledge of the challenges in that market. Tim’s expertise is widely varied and includes developing effective pricing strategies that balance stakeholder needs and collaborating cross-functionally to engage decision-makers. He is adept at building high functioning teams and developing successful commercial strategies to optimize patient access.

With a proven track record of success, he is committed to driving positive outcomes for his organization and the patients it serves. Tim has played an important role in the launch of 3 products since 2019: Cablivi for acute Thrombotic Thrombocytopenia purpura (aTTP),  Lupkinis for lupus nephritis, and now Gohibic for critically ill Covid patients.

Quick Links
  • Impressum
  • Privacy
  • Products & Technology
  • News
  • Career
  • Disclaimer
  • Contact
  • Newsletter
Contact Jena

InflaRx N.V. / InflaRx GmbH
Winzerlaer Str. 2
07745 Jena

+49 3641 508 180

info@inflarx.de

InflaRx on Linkedin

Contact Munich

InflaRx N.V. / InflaRx GmbH
Fraunhoferstraße 22
82152 Martinsried

+49 89 414 189 78 00

info@inflarx.de

Contact Ann Arbor

InflaRx Pharmaceuticals Inc.
600 S. Wagner Rd.
Ann Arbor, MI 48103

info@inflarx.de

© Copyright 2017 All Rights Reserved.
  • Developed by Ementals